Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Recruiting 24Active not recruiting 17Completed 8Unknown 5Withdrawn 4Terminated 3Not yet recruiting 2Suspended 1

Sponsor Class

OTHER 7INDUSTRY 1

Study Type

Interventional 8Observational 4

Sponsor

Cancer Type

NET 5Endocrine 5Thoracic 1CNS 1

Conditions

Neuroendocrine Tumors 5Somatostatinoma 1Small Cell Lung Carcinoma 1Neuroblastoma 1

Interventions

Cyclophosphamide 1492Cisplatin 1414Paclitaxel 1317Radiotherapy 1261Carboplatin 1250Gemcitabine 1215Docetaxel 1109Bevacizumab 1030Fluorouracil 894Doxorubicin 792Dexamethasone 748Rituximab 719Capecitabine 716Oxaliplatin 700pembrolizumab 680Etoposide 678Irinotecan 634Filgrastim 621Cytarabine 586Leucovorin 579Nivolumab 558Vincristine 515Prednisone 475Cetuximab 465Bortezomib 459Erlotinib Hydrochloride 456Trastuzumab 447Methotrexate 438Lenalidomide 427Pemetrexed 420

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
Completed × Interventional × lutetium Lu 177 dotatate × Clear all
NCT03966651 2026-04-29

NEUROBLU 02

Institut Claudius Regaud

Phase 1 Completed
1 enrolled
CNS

Neuroblastoma

NCT02230176 2025-04-20

OCCLURANDOM

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Completed
84 enrolled

Somatostatinoma

NCT04385992 2023-06-27

NeoLuPaNET

IRCCS San Raffaele

Phase 2 Completed
31 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT01237457 2023-03-20

177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms

Excel Diagnostics and Nuclear Oncology Center

Phase 2 Completed
143 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT01842165 2022-11-10

LUMEN

Jules Bordet Institute

Phase 3 Completed
37 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03590119 2022-11-08

LUTIA

UMC Utrecht

Phase 2/3 Completed
26 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT01578239 2022-04-04

NETTER-1

Advanced Accelerator Applications

Phase 3 Completed
231 enrolled 16 charts 2 FDA
EndocrineNET

Neuroendocrine Tumors

NCT03325816 2021-03-16

Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer

Georgetown University

Phase 1/2 Completed
9 enrolled 10 charts
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡